Protein Alternatives SL (ProAlt) is a biotechnology company founded in 2006 and headquartered in Madrid, Spain. ProAlt’s mission is the development and commercialization of biomarker-based assays for early cancer diagnosis and the development of therapeutic monoclonal antibodies for the treatment of metastatic cancers. ProAlt’s main priority is the development of a test for screening and early diagnosis of colorectal cancer in population at risk, requiring only a conventional blood extraction. This product should offer significant advantages over current diagnostic tools, offering a considerable higher detection capacity, simple usage and a reduced cost when compared with high complexity technologies like colonoscopy, an invasive test with potential relevant side effects. The company strength is a deep knowledge of protein and antibody design, development and production. In this sense, ProAlt’s additional goal is to offer different products and custom-tailored services, mainly related to proteins and antibodies production and/or protein expression, to meet the needs of the academic and biotechnology industry. The company offers own-manufactured innovative proteins and antibodies, some of them exclusively provided by ProAlt, and specialized services in protein design and production based on three different expression systems: E. coli (bacterial), Baculovirus in insect cells and mammalian cells. For more information: http://www.proteinalternatives.com